Drug utilization studies from secondary databases in latent tuberculosis: a scoping review protocol
DOI:
https://doi.org/10.30968/rbfhss.2024.151.1076Abstract
This article introduces a protocol for a scoping review that aims to map and synthesize Drug utilization studies from secondary databases in latent tuberculosis The protocol is intended to document the processes involved in the methodological planning and execution of a scoping review guided by Joanna Briggs Institute guidelines and developed using the 2015 PRISMA-Protocols (PRISMA-P) checklist. The PCC strategy (population, concept and context) systematized the search for studies published in Pubmed, Scopus, BVS, Embase and Web of Science from January 2015 to December 2022. The selection of articles will be carried out in two steps (titles and abstracts, followed by the assessment of the full text of the articles), by two independent reviewers, with the resolution of disagreements by a third reviewer. The results will be analyzed qualitatively/quantitatively and will be organized by themes. The checklist present in the Preferred Reporting Items for Systematic Reviews and Meta-Analysis extension for Scoping Reviews (PRISMA-ScR) will be used to guide the final review report. We hope that this scoping review will shed light on Drug Utilization Research in the field of latent tuberculosis, which is still understudied, especially in Brazil.
Downloads
References
World Health Organisation. The END TB Strategy Global Strategy and Targets for Tuberculosis Prevention, Care and Control after 2015. WHO Press: Geneva, Switzerland; 2014.
Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis. Coordenação Geral do Programa Nacional de Controle da Tuberculose. Plano Nacional Pelo Fim Da Tuberculose Como Problema de Saúde Pública. Brasilia (DF); 2017.
Ministério da Saúde. Secretaria de Vigilância em Saúde (SVS). Protocolo de vigilância da infecção latente pelo Mycobacterium tuberculosis no Brasil. MS, Ministério da Saúde: Brasilia (DF); 2018.
Brasil. Ministério da Saúde. Manual de Recomendações Para o Controle Da Tuberculose No Brasil. Brasília Df; 2019.
World Health Organisation. Global Tuberculosis Report. WHO Press: Geneva, Switzerland; 2020.
Fox GJ, Nguyen TA, Coleman M, et al. Implementing tuberculosis preventive treatment in high-prevalence settings. Int J Infect Dis 2021;113 Suppl 1:S13–S15; doi: 10.1016/j.ijid.2021.02.094.
Hijjar MA, Gerhardt G, Teixeira GM, et al. Retrospecto do controle da tuberculose no Brasil. Revista de Saúde Pública 2007;41:50–57; doi: 10.1590/S0034-89102007000800008.
Luiz Villarinho. La Pharmaceuticalisation de La Lutte Contre La Tuberculose Au Brésil : Circulations de Politiques et de Savoirs à La Lumière Des Archives et Des Témoignages de l’oms et d’autres Acteurs de La Scène Internationale de La Santé (1967 à Nos Jours). École des Hautes Études en Sciences Sociales: Paris, France; 2021.
Leal LF, Osorio-de-Castro CGS, Souza LJC de, et al. Data Sources for Drug Utilization Research in Brazil—DUR-BRA Study. Front Pharmacol 2022;12:789872; doi: 10.3389/fphar.2021.789872.
Osorio-de-castro CGS, Mosegui GBG, Peixoto MAP, et al. Estudos de utilização de medicamentos : noções básicas. Editora Fiocruz: Rio de Janeiro; 2000.
Ministério da Saúde. Coordenação de Monitoramento e Avaliação de Tecnologias em Saúde. Rifapentina + Isoniazida Para o Tratamento Da Infecção Latente Pelo Mycobacterium Tuberculosis (ILTB). CONITEC: Brasilia; 2020.
Arksey H, O’Malley L. Scoping studies: towards a methodological framework. International Journal of Social Research Methodology 2005;8(1):19–32; doi: 10.1080/1364557032000119616.
Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med 2018;169(7):467–473; doi: 10.7326/M18-0850.
Aromataris E, Munn Z, (eds). JBI Manual for Evidence Synthesis. JBI; 2020.; doi: 10.46658/JBIMES-20-01.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
